EXAI vs. ITOS, ADPT, VALN, HLVX, KYTX, CABA, ALEC, ALLO, TSHA, and FATE Should you be buying Exscientia stock or one of its competitors? The main competitors of Exscientia include iTeos Therapeutics (ITOS), Adaptive Biotechnologies (ADPT), Valneva (VALN), HilleVax (HLVX), Kyverna Therapeutics (KYTX), Cabaletta Bio (CABA), Alector (ALEC), Allogene Therapeutics (ALLO), Taysha Gene Therapies (TSHA), and Fate Therapeutics (FATE). These companies are all part of the "biological products, except diagnostic" industry.
Exscientia (NASDAQ:EXAI ) and iTeos Therapeutics (NASDAQ:ITOS ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, community ranking, dividends, earnings, profitability, valuation and institutional ownership.
iTeos Therapeutics has a net margin of 0.00% compared to Exscientia's net margin of -737.10%. iTeos Therapeutics' return on equity of -23.15% beat Exscientia's return on equity.
Exscientia has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500.
In the previous week, Exscientia and Exscientia both had 16 articles in the media. iTeos Therapeutics' average media sentiment score of 0.87 beat Exscientia's score of 0.05 indicating that iTeos Therapeutics is being referred to more favorably in the news media.
iTeos Therapeutics has lower revenue, but higher earnings than Exscientia. iTeos Therapeutics is trading at a lower price-to-earnings ratio than Exscientia, indicating that it is currently the more affordable of the two stocks.
iTeos Therapeutics received 21 more outperform votes than Exscientia when rated by MarketBeat users. Likewise, 73.17% of users gave iTeos Therapeutics an outperform vote while only 36.00% of users gave Exscientia an outperform vote.
41.6% of Exscientia shares are held by institutional investors. Comparatively, 97.2% of iTeos Therapeutics shares are held by institutional investors. 16.4% of Exscientia shares are held by company insiders. Comparatively, 10.2% of iTeos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Exscientia presently has a consensus price target of $9.75, indicating a potential upside of 87.50%. iTeos Therapeutics has a consensus price target of $31.00, indicating a potential upside of 71.75%. Given Exscientia's higher possible upside, equities research analysts plainly believe Exscientia is more favorable than iTeos Therapeutics.
Summary iTeos Therapeutics beats Exscientia on 12 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding EXAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Exscientia Competitors List
Related Companies and Tools
